文献速递胸部肿瘤

EGFR突变NSCLC免疫检查点抑制剂:黄昏还是黎明?

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
PubMed 文献 · J Thorac Oncol · 2021-04-26

该综述总结了ICIs在EGFR突变NSCLC患者中的临床疗效证据,指出PD-L1表达和TMB等预测生物标志物在EGFR突变肿瘤中无效,提示其肿瘤微环境具有独特性。文章通过癌症免疫图特征描绘了EGFR突变NSCLC的免疫系统相互作用状态,并讨论了可能从ICI治疗中获益的潜在亚群及未来联合免疫治疗策略。

要点

  • ICIs在EGFR突变NSCLC中临床获益有限,PD-L1和TMB等标志物预测无效。
  • EGFR突变NSCLC肿瘤微环境具有独特特征,需综合免疫图评估。
  • 未来需探索联合免疫治疗策略以最大化ICI疗效。

核心结论

  • ICIs在EGFR突变NSCLC患者中临床获益有限,需探索联合策略。

研究设计与样本

  • 综述,总结ICIs在EGFR突变NSCLC中的临床证据并描绘癌症免疫图特征。

主要发现

  • PD-L1表达和TMB等预测生物标志物在EGFR突变肿瘤中无效。
  • EGFR突变NSCLC的肿瘤微环境具有独特特征,涉及肿瘤外来性、免疫效应敏感性、代谢、免疫状态、免疫细胞浸润、细胞因子和可溶性分子。

临床怎么用

  • 不应依赖PD-L1或TMB筛选EGFR突变NSCLC患者接受ICI治疗。
  • 需通过癌症免疫图综合评估免疫状态,并探索联合免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in advanced NSCLC, clinical benefits of these agents are limited in patients with EGFR-mutated NSCLC. Several predictive biomarkers (e.g., programmed cell death ligand-1 expression, tumor mutation burden), which have been validated in EGFR-wild type NSCLC, however, are not efficacious in EGFR-mutated tumors, suggesting the unique characteristics of tumor microenvironment of EGFR-mutated NSCLC. Here, we first summarized the clinical evidence on the efficacy of ICIs in patients with EGFR-mutated NSCLC. Then, the cancer immunogram features of EGFR-mutated NSCLC was depicted to visualize the state of cancer-immune system interactions, including tumor foreignness, tumor sensitivity to immune effectors, metabolism, general immune status, immune cell infiltration, cytokines, and soluble molecules. We further discussed the potential subpopulations with EGFR mutations that could benefit from ICI treatment. Lastly, we put forward future strategies to adequately maximize the efficacy of ICI treatment in patients with EGFR-mutated NSCLC in the upcoming era of combination immunotherapies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Qiao M, Jiang T, Liu X, et al. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn? J Thorac Oncol. 2021. PMID: 33915248. doi:10.1016/j.jtho.2021.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。